Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 1, 2013, Pages 78-89

  Ciuclan, Loredana ^a   Hussey, Martin J ^a   Burton, Victoria ^a   Good, Robert ^a   Duggan, Nicholas ^a   Beach, Sarah ^a   Jones, Peter ^a   Fox, Roy ^a   Clay, Ieuan ^b   Bonneau, Olivier ^a   Konstantinova, Irena ^a   Pearce, Andrew ^a   Rowlands, David J ^a   Jarai, Gabor ^a   Westwick, John ^a   MacLean, Margaret R ^c   Thomas, Matthew ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Animal preclinical models; Imatinib; Platelet derived growth factor receptor; Pulmonary arterial hypertension

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SEROTONIN; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HYPOXIA; LUNG HEMODYNAMICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; BENZAMIDES; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HYPERTENSION, PULMONARY; INDOLES; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

EID: 84871985829     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201206-1028OC     Document Type: Article

References (52)

1. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S20-S31.
2. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:1239-1247.
3. O'Callaghan DS, Savale L, Montani D, Jais X, Sitbon O, Simonneau G, Humbert M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol. 2011;8:526-538.
4. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat.Rev.Cardiol. 2011;8:443-455.
5. Fares WH, Trow TK. Targeted approaches to the treatment of pulmonary hypertension. Ther Adv Respir Dis 2012;6:147-159.
6. Chhina MK, Nargues W, Grant GM, Nathan SD. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol 2010;6:19-35.
7. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-88. (Pubitemid 351919196)
8. ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 2012;21:119-134.
9. 2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2012;302:C405-C411.
10. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54:S10-S19.
11. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821. (Pubitemid 41434408)
12. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003;284:L826-L833. (Pubitemid 36459029)
13. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010;18:6977-6986.
14. Ruiz PA, Jarai G. Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem 2011;286:12912-12923.
15. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53.
16. MacLean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol 2010;661:309-322.
17. MacLean MR. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci 1999;20:490-495. (Pubitemid 30004021)
18. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-168.
19. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:2812-2819. (Pubitemid 40791554)
20. Jaffre F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 2009;104:113-123.
21. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006;113:1857-1864. (Pubitemid 43739397)
22. Eddahibi S, Adnot S. Serotonin and pulmonary arterial hypertension. Rev Mal Respir 2006;23:S45-S51.
23. Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur AM, Saurini F, Eddahibi S, Hamon M, Adnot S. Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 2007;293:L1045-L1052. (Pubitemid 47572253)
24. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007;49:232-236. (Pubitemid 46360365)
25. Ren W, Watts SW, Fanburg BL. Serotonin transporter interacts with the PDGFbeta receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2011;300:L486-L497.
26. Liu Y, Li M, Warburton RR, Hill NS, Fanburg BL. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J 2007;21:2725-2734. (Pubitemid 47372740)
27. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182.
28. Ciuclan L, Bonneau O, Hussey M, Burton V, Good R, Duggan N, Thomas M. The roles of TPH1, serotonin and PDGF within a novel murine model of pulmonary arterial hypertension [abstract]. 2011. Am J Respir Crit Care Med 2011;183:A4962.
29. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, et al. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008;135:642-659.
30. Tran VS, Marion-Audibert AM, Karatekin E, Huet S, Cribier S, Guillaumie K, Chapuis C, Desnos C, Darchen F, Henry JP. Serotonin secretion by human carcinoid BON cells. Ann N Y Acad Sci 2004;1014:179-188. (Pubitemid 38594804)
31. Burton VJ, Ciuclan LI, Holmes AM, Rodman DM, Walker C, Budd DC. Bone morphogenetic protein receptor-II regulates pulmonary artery endothelial cell barrier function. Blood 2011;117:333-341.
32. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and Mat- Inspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-4884. (Pubitemid 3008389)
33. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M,Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-2942. (Pubitemid 40916416)
34. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413. (Pubitemid 41362714)
35. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177.
36. Dahal BK, Heuchel R, Pullamsetti SS,Wilhelm J, Ghofrani HA,Weissmann N, Seeger W, Grimminger F, Schermuly RT. Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-b. Pulm Circ 2011;1:259-268.
37. Humbert M, Montani D, Perros F, Dorfmuller P, Adnot S, Eddahibi S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 2008;49:113-118.
38. Agarwal A, Fleischman AG, Petersen CL, Loriaux MM, Woltjer R, Druker BJ, Deininger MW. Effects of plerixafor (AMD3100) in combination with tyrosine kinase inhibition in a murine model of CML. Blood 2010;116:1387-1388.
39. Heresi GA. Clinical perspective: biomarkers in pulmonary arterial hypertension. Int J Clin Pract 2011;65:5-7.
40. Koyanagi M, Egashira K, Kitamoto S, Ni WH, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 2000;102:2243-2248.
41. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension- from bench to bedside? Curr Opin Pharmacol 2009;9:281-286.
42. McLaughlin VV, Davis M, Cornwell W. Pulmonary arterial hypertension. Curr Probl Cardiol 2011;36:461-517.
43. Dumitrascu R, Kulcke C, Konigshoff M, Kouri F, Yang X, Morrell N, Ghofrani HA, Weissmann N, Reiter R, Seeger W, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 2011;37:1104-1118.
44. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto SI. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002;119:106-108. (Pubitemid 35176504)
45. Pocock R, Hobert O. Oxygen levels affect axon guidance and neuronal migration in Caenorhabditis elegans. Nat Neurosci 2008;11:894-900.
46. Yao JC, Zhang JX, Rashid A, Yeung SCJ, Szklaruk J, Hess K, Xie KP, Ellis L, Abbruzzese JL, Ajani J. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-240. (Pubitemid 46121874)
47. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004;109:2150-2155. (Pubitemid 38620226)
48. Konigshoff M, Dumitrascu R, Udalov S, Amarie OV, Reiter R, Grimminger F, Seeger W, Schermuly RT, Eickelberg O. Increased expression of 5-hydroxytryptamine(2A/B) receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax 2010;65:949-955.
49. Maclean M, Morecroft I, Dempsie Y. The serotonin transporter in pulmonary arterial hypertension. Fundam Clin Pharmacol 2008;22:24.
50. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM. Novel interactions between the 5-HT transporter, 5-HT(1B) receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 2008;155:606-616.
51. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, Baker AH, MacLean MR. Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics 2011;43:417-437.
52. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17 beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011;90:373-382.